Finding a Cancer Treatment (NCI-)MATCH
NCI-MATCH precision medicine trial provides insight into tumor gene testing for targeted cancer treatment
Olivia Gaskill | | Quick Read
In 2015, the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI) teamed up to run the largest precision medicine cancer trial to date – the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH). The aim? To test the genetic profile of tumors and match patients to targeted treatments without limiting the trial to one type of cancer or to approved drugs (1).
Before the trial, the frequency of tumor gene abnormalities across cancer types was unknown. But the study found a 37.6 percent chance of a tumor’s having a defect that matches a targeted drug – a rate that the researchers hope will demonstrate to clinicians the value of genetic testing. Match rate varied across cancer types, with rarer cancers matching at higher rates than more common types – highlighting the lack of targeted treatments for mutations within those cancers. It was also common for several tumor gene abnormalities to drive cancer growth simultaneously, suggesting that combination therapies may be effective for many patients.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine